Novo Nordisk’s CagriSema and Eli Lilly’s orforglipron are both making waves in the weight loss market. CagriSema, a dual agonist, is showing promise as a new growth driver for Novo Nordisk. Meanwhile, orforglipron, Eli Lilly’s breakthrough anti-obesity medicine, is poised to enter the market with positive phase 3 results and potential FDA approval. While Eli Lilly seems to have a lead with Zepbound and orforglipron, Novo Nordisk’s CagriSema could still be a strong contender. Investors may want to keep an eye on both companies as they navigate the rapidly expanding weight loss market.

Read more at Nasdaq: The Weight Loss Drug Competition Is Heating Up: These 2 Industry Leaders Just Filed Competing Drugs with the FDA.